Rafferty Asset Management
RGNX icon

Rafferty Asset Management’s Regenxbio RGNX Stock Holding History

Rafferty Asset Management’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$652K Sell
54,451
-19,427
-26% -$161K ﹤0.01% 849
2026
Q1 		$619K Buy
73,878
+14,679
+25% +$154K ﹤0.01% 862
2025
Q4 		$852K Sell
59,199
-6,660
-10% -$83K ﹤0.01% 825
2025
Q3 		$636K Buy
65,859
+5,204
+9% +$46K ﹤0.01% 869
2025
Q2 		$498K Buy
+60,655
New +$508K ﹤0.01% 887
2025
Q1 		– Sell
-93,821
Closed -$725K – 1133
2024
Q4 		$725K Buy
93,821
+17,180
+22% +$161K ﹤0.01% 849
2024
Q3 		$804K Sell
76,641
-26,549
-26% -$324K ﹤0.01% 841
2024
Q2 		$1.21M Sell
103,190
-76,678
-43% -$1.19M ﹤0.01% 773
2024
Q1 		$3.79M Buy
179,868
+59,035
+49% +$1.05M 0.01% 528
2023
Q4 		$2.17M Sell
120,833
-11,020
-8% -$194K 0.01% 654
2023
Q3 		$2.17M Sell
131,853
-25,135
-16% -$455K 0.01% 588
2023
Q2 		$3.14M Buy
156,988
+27,973
+22% +$539K 0.02% 511
2023
Q1 		$2.44M Sell
129,015
-14,232
-10% -$315K 0.02% 549
2022
Q4 		$3.25M Buy
143,247
+26,140
+22% +$591K 0.03% 466
2022
Q3 		$3.1M Buy
117,107
+38,914
+50% +$1.15M 0.03% 412
2022
Q2 		$1.93M Sell
78,193
-38,447
-33% -$961K 0.02% 472
2022
Q1 		$3.87M Buy
116,640
+576
+0.5% +$16K 0.02% 435
2021
Q4 		$3.79M Buy
116,064
+45,285
+64% +$1.54M 0.02% 476
2021
Q3 		$2.97M Buy
70,779
+6,689
+10% +$241K 0.02% 484
2021
Q2 		$2.49M Sell
64,090
-17,619
-22% -$630K 0.02% 603
2021
Q1 		$2.79M Buy
81,709
+69,400
+564% +$2.96M 0.02% 535
2020
Q4 		$558K Sell
12,309
-33,457
-73% -$1.17M 0.01% 657
2020
Q3 		$1.26M Buy
45,766
+24,496
+115% +$799K 0.02% 542
2020
Q2 		$783K Buy
+21,270
New +$793K 0.01% 609
2020
Q1 		– Sell
-49,799
Closed -$2.04M – 763
2019
Q4 		$2.04M Sell
49,799
-66,856
-57% -$2.64M 0.03% 385
2019
Q3 		$4.15M Buy
116,655
+21,015
+22% +$852K 0.06% 178
2019
Q2 		$4.91M Buy
95,640
+37,742
+65% +$1.88M 0.09% 171
2019
Q1 		$3.32M Buy
+57,898
New +$2.87M 0.05% 197

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Rafferty Asset Management's RGNX Position: Q2 2026 in Review

Rafferty Asset Management reduced its Regenxbio (RGNX) stake by 26% in Q2 2026, selling an estimated $161K and leaving 54,451 shares worth $652K. The position accounts for ﹤0.01% of the portfolio, ranked #849.

Rafferty Asset Management first reported a position in RGNX in Q1 2019 and has held it in 28 quarters since. The position peaked at $4.91M in Q2 2019. 165 funds tracked by Wall St. Rank hold RGNX as of Q2 2026.

  • Rafferty Asset Management held 54,451 shares of Regenxbio worth $652K as of Q2 2026.
  • Rafferty Asset Management sold 19,427 Regenxbio shares in Q2 2026, an estimated $161K.
  • Regenxbio made up ﹤0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #849 holding.
  • Rafferty Asset Management first reported a position in Regenxbio in Q1 2019 and has held it in 28 quarters since.
  • Rafferty Asset Management's Regenxbio position peaked at $4.91M in Q2 2019.
  • 165 funds tracked by Wall St. Rank held Regenxbio as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.